Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Forxiga dapagliflozin regulatory update

The U.K.'s NICE issued final guidance recommending the use of Forxiga dapagliflozin from Bristol-Myers and partner AstraZeneca as an add-on to metformin or insulin to treat Type II diabetes. Forxiga

Read the full 308 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE